ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

C4XD C4x Discovery Holdings Plc

12.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 12.00 10.30 10.80 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.71M -11.11M -0.0441 -2.72 30.27M

C4X Discovery Holdings PLC Cancellation and Regrant of Existing Share Options (5136U)

29/07/2020 2:54pm

UK Regulatory


C4x Discovery (LSE:C4XD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more C4x Discovery Charts.

TIDMC4XD

RNS Number : 5136U

C4X Discovery Holdings PLC

29 July 2020

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Cancellation and Regrant of Existing Share Options

2 9 July 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that it is to cancel and reissue a number of unexpired options to subscribe for its ordinary shares of 0.1p each ("Ordinary Shares") which have been held by various employees and the Directors of the Company since their grant between 2015 and 2018 (the "Regrant").

The Regrant brings the strike price of the share options into line with the current market price of the Company's shares and should now deliver a viable incentive and reward package to the employees and Directors of the Company.

The Regrant options have an exercise price of 16p, being the closing price of the Ordinary Shares on 28 July 2020. The options can be exercised at any time between 3 years and 10 years of them being granted.

The share option holdings by the Directors of C4X Discovery before and after the Regrant are summarised as follows:

 
                             Options before Regrant                                                Options following 
                                                                                                    Regrant 
             Expiry Date     08-Jun-15   08-Dec-15   23-Nov-16   01-Feb-17   15-May-18             28-Jul-20 
            --------------  ----------  ----------  ----------  ----------  ----------  --------  ----------  -------- 
 Director    Strike Price      GBP1.00     GBP0.77     GBP1.05     GBP0.91    GBP0.892     Total     GBP0.16     Total 
              pence per 
              Share 
            --------------  ----------  ----------  ----------  ----------  ----------  --------  ----------  -------- 
             Chief 
 Clive        Executive 
  Dix         Officer           20,000     125,000           0           0      50,000   195,000     195,000   195,000 
            --------------  ----------  ----------  ----------  ----------  ----------  --------  ----------  -------- 
             Chief 
 Brad         Financial 
  Hoy         Officer                0           0     300,000           0      50,000   350,000     350,000   350,000 
            --------------  ----------  ----------  ----------  ----------  ----------  --------  ----------  -------- 
             Chief 
 Craig        Scientific 
  Fox         Officer          150,000           0                  50,000      50,000   250,000     250,000   250,000 
            --------------  ----------  ----------  ----------  ----------  ----------  --------  ----------  -------- 
 
 TOTAL OPTIONS 
  OUTSTANDING                  170,000     125,000     300,000      50,000     150,000   795,000     795,000   795,000 
                            ----------  ----------  ----------  ----------  ----------  --------  ----------  -------- 
 

- Ends -

Contacts

 
 C4X Discovery Holdings 
 Mo Noonan, Communications                    +44 (0)787 6444977 
 
 Panmure Gordon (UK) Limited (NOMAD and 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate 
  Finance)                                    +44 (0)20 7886 2500 
 James Stearns (Corporate Broking) 
 
 C4X Discovery Media - Consilium Strategic 
  Communications 
 Mary-Jane Elliott, Chris Gardner, Matthew 
  Neal                                        +44 (0)203 709 5700 
 

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to: www.c4xdiscovery.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCSEFFDUESSEIW

(END) Dow Jones Newswires

July 29, 2020 09:54 ET (13:54 GMT)

1 Year C4x Discovery Chart

1 Year C4x Discovery Chart

1 Month C4x Discovery Chart

1 Month C4x Discovery Chart

Your Recent History

Delayed Upgrade Clock